EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevention of HBV Mother‐To‐Child Transmission ( MTCT ) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda

Samantha Hall iD, Ponsiano Ocama iD, Danielle Leavelle, Julius Kiwanuka iD, Brian Lwanga, Joan Nankya-Mutyoba iD, Calvin Q Pan iD, Christine Namulindwa, Viola Kasone iD, Rachel Beyagira, Homie Razavi iD

Journal of Viral Hepatitis · 2026-08 · 33 (8)

DOI: 10.1111/jvh.70215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 28.07.2026. Verfasst von Samantha Hall und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Disease Analysis Foundation, Lafayette, USA. Hauptthemen laut MEDLINE: Infectious Disease Transmission, Vertical, Viral Load, Pregnancy Complications, Infectious, Antiviral Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: John C. Martin Foundation, Ministry of Health, Uganda.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) mother‐to‐child transmission (MTCT) remains a major challenge in Uganda, where 43% of births occur at home, and access to timely birth dose (BD) vaccination is limited. We evaluated the impact of combining universal three‐dose (3D) infant vaccination, targeted BD vaccination, and maternal antiviral treatment for high viral load (HVL) mothers on HBV prevalence among infants. In a prospective 18‐month cohort study at five regional maternity hospitals, HIV‐negative pregnant women were screened for HBsAg. HBsAg‐positive mothers were stratified by HBV DNA into HVL (≥ 20,000 IU/mL), low viral load (LVL), or LVL on treatment. HVL mothers received Tenofovir Disoproxil Fumarate plus Lamivudine in the third trimester. Infants of HBsAg‐positive mothers received BD vaccination within 24 h and the 3D pentavalent series; infants of HBsAg‐negative mothers received the 3D series only. All infants were tested for HBsAg at nine months. Of 19,053 mothers screened, 3.46% were HBsAg‐positive ( n = 660). Among HVL mothers ( n = 80), 96.3% initiated antivirals; none of their infants who received both BD and 3D tested HBsAg‐positive. Among LVL mothers not on treatment ( n = 558), the prevalence of infection at nine months was 0.4% despite full vaccination. No infections occurred among LVL mothers on treatment or among infants of HBsAg‐negative mothers. Overall infant HBsAg prevalence was 0.19%, with an adjusted national estimate of 0.02%. Integrating maternal antiviral prophylaxis, targeted BD vaccination, and universal 3D vaccination achieved near‐elimination of HBV MTCT in this setting. Nationally scaling this strategy could enable Uganda to meet the WHO target of less than 0.1% infant HBV prevalence before 2030 and serve as a model for other high‐burden countries with significant rates of home births.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infectious Disease Transmission, VerticalViral LoadPregnancy Complications, InfectiousAntiviral AgentsHepatitis BHepatitis B VaccinesHumansFemalePregnancyUgandaAdultProspective StudiesInfantInfant, NewbornYoung AdultHepatitis B Surface AntigensHepatitis B virusPrevalenceLamivudineVaccination

Stichwörter der Autor:innen

hepatitis B virusmother‐to‐child transmissiontargeted birth dosetreatment of pregnant women

Substanzen

Antiviral AgentsHepatitis B VaccinesHepatitis B Surface AntigensLamivudine

Autor:innen und Institutionen

  • Center for Disease Analysis Foundation, Lafayette, USA.
  • School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
  • School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
  • Makerere Lung Institute, Kampala, Uganda.
  • Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, NYU Grossman School of Medicine, New York, USA.
  • Ministry of Health, Central Public Health Laboratories, Kampala, Uganda.

ORCID-Profile: Samantha Hall, Ponsiano Ocama, Julius Kiwanuka, Joan Nankya-Mutyoba, Calvin Q Pan, Viola Kasone, Homie Razavi

Förderung

  • John C. Martin Foundation
  • Ministry of Health, Uganda

Zitieren

APA

Hall, S., Ocama, P., Leavelle, D., Kiwanuka, J., Lwanga, B., Nankya-Mutyoba, J., Pan, C. Q., Namulindwa, C., Kasone, V., Beyagira, R., & Razavi, H. (2026). Prevention of HBV Mother‐To‐Child Transmission ( MTCT ) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda. Journal of Viral Hepatitis, 33(8). https://doi.org/10.1111/jvh.70215

Vancouver

Hall S, Ocama P, Leavelle D, Kiwanuka J, Lwanga B, Nankya-Mutyoba J, et al. Prevention of HBV Mother‐To‐Child Transmission ( MTCT ) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda. Journal of Viral Hepatitis. 2026;33(8). doi:10.1111/jvh.70215

BibTeX
@article{Hall2026,
  author = {Hall, Samantha and Ocama, Ponsiano and Leavelle, Danielle and Kiwanuka, Julius and Lwanga, Brian and Nankya-Mutyoba, Joan and Pan, Calvin Q and Namulindwa, Christine and Kasone, Viola and Beyagira, Rachel and Razavi, Homie},
  title = {Prevention of HBV Mother‐To‐Child Transmission ( MTCT ) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  volume = {33},
  number = {8},
  doi = {10.1111/jvh.70215}
}
Kostenlos starten →